Current Report Filing (8-k)
June 14 2017 - 04:08PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
June 14, 2017 (June 14, 2017)
Date of Report (Date of earliest event reported)
ELITE PHARMACEUTICALS, INC.
(Exact name of registrant
as specified in its charter)
Nevada
|
|
001-15697
|
|
22-3542636
|
(State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
165 Ludlow Avenue, Northvale, New Jersey
07647
(Address of principal
executive offices)
(201) 750-2646
(Registrant’s telephone number, including
area code)
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations
and Financial Condition.
On June 14, 2017, Elite Pharmaceuticals, Inc. ("Elite"
or the “Company") filed its annual report on Form 10-K for the year ended March 31, 2017 and, thereafter, issued a press
release announcing its financial results for the fourth quarter and the fiscal year 2017 then ended. A copy of the press release
is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
As noted in the press release, the Company will host a conference
call at 2:00 PM Eastern Daylight Time (EDT) on Thursday, June 15, 2017, to provide a general business update. Elite will respond
to various stockholder questions submitted prior to the call.
Conference Call Information
Date:
|
Thursday, June 15, 2017
|
Time:
|
2:00 PM EST
|
Dial-in numbers:
|
1-800-346-7359 (domestic)
|
|
1-973-528-0008 (international)
|
Conference number:
|
98840
|
Questions:
|
dianne@elitepharma.com
by 9:00 AM on Thursday, June 15, 2017
|
Audio Replay:
|
http://ir.elitepharma.com/events_presentations
|
Item 7.01 Regulation FD Disclosure.
The information disclosed in Item 2.02 above is incorporated
into this Item 7.01. The information included in this Current Report on Form 8-K (including the exhibit hereto) is being furnished
under Item 2.02, "Results of Operations and Financial Condition," Item 7.01, "Regulation FD Disclosure" and
Item 9.01 "Financial Statements and Exhibits" of Form 8-K. As such, the information (including the exhibit) herein shall
not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into a filing under
the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing,
except as shall be expressly set forth by specific reference in such a filing. This Current Report (including the exhibit hereto)
will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements
of Regulation FD.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
|
|
Description
|
99.1
|
|
Press Release dated June 14, 2017
|
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 14, 2017
|
ELITE PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/s/ Nasrat Hakim
|
|
|
Nasrat Hakim, President and CEO
|
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Feb 2024 to Mar 2024
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Mar 2023 to Mar 2024